However, since SMYD2 plays diverse roles in different cells and organs by regulating distinct substrates, side effects may be unavoidable if SMYD2 inhibitors are used as therapeutic targets in ADPKD. This evidence concerns the gene SMYD2 and autosomal dominant polycystic kidney disease.